169 related articles for article (PubMed ID: 32303902)
21. miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction.
Gigante M; Pontrelli P; Herr W; Gigante M; D'Avenia M; Zaza G; Cavalcanti E; Accetturo M; Lucarelli G; Carrieri G; Battaglia M; Storkus WJ; Gesualdo L; Ranieri E
J Transl Med; 2016 Apr; 14():84. PubMed ID: 27063186
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of immunological profile based on CD8+ and FoxP3+ T lymphocytes in the peritumoral and intratumoral subsites for renal cell carcinoma.
Teke K; Yaprak Bayrak B; Yuksekkaya M; Uslubas AK; Kosem ME; Yilmaz H; Kara O; Dillioglugil O
Int Urol Nephrol; 2020 Dec; 52(12):2289-2299. PubMed ID: 32761342
[TBL] [Abstract][Full Text] [Related]
23. EZH2 enhances the invasive capability of renal cell carcinoma cells via activation of STAT3.
Zhang D; Yang XJ; Luo QD; Fu DL; Li HL; Li HC; Zhang P; Chong T
Mol Med Rep; 2018 Mar; 17(3):3621-3626. PubMed ID: 29286132
[TBL] [Abstract][Full Text] [Related]
24. Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder.
Hinz S; Kempkensteffen C; Christoph F; Hoffmann M; Krause H; Schrader M; Schostak M; Miller K; Weikert S
J Cancer Res Clin Oncol; 2008 Mar; 134(3):331-6. PubMed ID: 17694325
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of extensive necrosis in renal cell carcinoma.
Collins J; Epstein JI
Hum Pathol; 2017 Aug; 66():108-114. PubMed ID: 28669641
[TBL] [Abstract][Full Text] [Related]
26. CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8(+) T cell frequency and patient survival.
Weiss JM; Gregory Alvord W; Quiñones OA; Stauffer JK; Wiltrout RH
Hum Immunol; 2014 Jul; 75(7):614-20. PubMed ID: 24801648
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Factors for Renal Cell Carcinoma Subtypes Diagnosed According to the 2016 WHO Renal Tumor Classification: a Study Involving 928 Patients.
Kuthi L; Jenei A; Hajdu A; Németh I; Varga Z; Bajory Z; Pajor L; Iványi B
Pathol Oncol Res; 2017 Jul; 23(3):689-698. PubMed ID: 28032311
[TBL] [Abstract][Full Text] [Related]
28. Reduced CDH16 expression is linked to poor prognosis in clear cell renal cell carcinoma 16.
Lennartz M; Csomós H; Bernreuther C; Büscheck F; Fraune C; Simon R; Sauter G; Steurer S; Eichenauer T; Dahlem R; Fisch M; Riechardt S; Rink M; Minner S; Höflmayer D
Urol Oncol; 2022 Jul; 40(7):348.e1-348.e8. PubMed ID: 35606285
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
[TBL] [Abstract][Full Text] [Related]
30. Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma.
Murakami T; Tanaka N; Takamatsu K; Hakozaki K; Fukumoto K; Masuda T; Mikami S; Shinojima T; Kakimi K; Tsunoda T; Sawada K; Imamura T; Mizuno R; Oya M
Cancer Immunol Immunother; 2021 Oct; 70(10):3001-3013. PubMed ID: 34259900
[TBL] [Abstract][Full Text] [Related]
31. Enhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising indicator of prognosis.
Yalçınkaya U; Uğraş N; Özgün G; Ocakoğlu G; Deligönül A; Çetintaş SK; Bilgen MS
Bosn J Basic Med Sci; 2017 Nov; 17(4):302-308. PubMed ID: 28738014
[TBL] [Abstract][Full Text] [Related]
32. Increased expression of EZH2 in Merkel cell carcinoma is associated with disease progression and poorer prognosis.
Harms KL; Chubb H; Zhao L; Fullen DR; Bichakjian CK; Johnson TM; Carskadon S; Palanisamy N; Harms PW
Hum Pathol; 2017 Sep; 67():78-84. PubMed ID: 28739498
[TBL] [Abstract][Full Text] [Related]
33. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
34. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
Choueiri TK; Figueroa DJ; Fay AP; Signoretti S; Liu Y; Gagnon R; Deen K; Carpenter C; Benson P; Ho TH; Pandite L; de Souza P; Powles T; Motzer RJ
Clin Cancer Res; 2015 Mar; 21(5):1071-7. PubMed ID: 25538263
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 expression and infiltration by CD4
Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
[TBL] [Abstract][Full Text] [Related]
36. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
37. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
38. The prognostic effect of immunoscore in patients with clear cell renal cell carcinoma: preliminary results.
Selvi I; Demirci U; Bozdogan N; Basar H
Int Urol Nephrol; 2020 Jan; 52(1):21-34. PubMed ID: 31541404
[TBL] [Abstract][Full Text] [Related]
39. Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor.
Singer K; Kastenberger M; Gottfried E; Hammerschmied CG; Büttner M; Aigner M; Seliger B; Walter B; Schlösser H; Hartmann A; Andreesen R; Mackensen A; Kreutz M
Int J Cancer; 2011 May; 128(9):2085-95. PubMed ID: 20607826
[TBL] [Abstract][Full Text] [Related]
40. Lymphocyte expression of EZH2 is associated with mortality and secondary infectious complications in sepsis.
Zhao D; Li Z; Liu X; Liu N; Bao X; Sun H; Meng Q; Ren H; Bai J; Zhou X; Tang L
Int Immunopharmacol; 2020 Dec; 89(Pt B):107042. PubMed ID: 33068867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
